Hema Now
In this episode of Hema Now, Kenneth Anderson from the Dana-Farber Cancer Institute, from Boston, USA, shares his expert insights in multiple myeloma research. From key takeaways from the recent ASH congress to efforts tackling drug resistance, and the challenges in translating laboratory science into the clinic, this episode is a must-watch.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (42 mins)
Kenneth Anderson is the Director of both the LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. He has dedicated his career to transforming the landscape of multiple myeloma, pioneering research that bridges laboratory discovery and real-world treatment innovation. His work has identified key targets within the tumour and its microenvironment, leading directly to multiple approved therapies and life-changing improvements in patient outcomes.
Timestamps:
00:00 – Introduction
01:10 – Overview of multiple myeloma
04:45 – Kenneth’s journey into medicine
07:44 – Myeloma microenvironment
13:40 – Bringing laboratory science to the bedside
16:18 – Exciting myeloma breakthroughs
24:00 – Targeting drug resistance
29:50 – Personalised medicine
34:20 – Importance of early intervention
39:40 – A message to those facing multiple myeloma
42:40 – Three magic wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
